Skip to content

Study · Randomized controlled trial · n = 50 · 2024

8 results

Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial.

Custódio G, Massutti AM, da Igreja MR, Lemos NE, Crispim D, Visioli F, Palma VM, Leitão CB, Rech TH

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society9 Nov 2023Cited by 6 (Europe PMC)

PMID37938130 (opens in a new tab)DOI10.1097/lvt.0000000000000298 (opens in a new tab)PepBankPUB-37938130
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide lowered the change in plasma IL-6 versus placebo.

    In plain wordsIn brain-dead organ donors, liraglutide lowered the rise in blood IL-6 compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in IL-6 plasma level
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Delta IL-6
    −28 pg/mL
    liraglutide
    Delta IL-6
    32 pg/mL
    placebo

    Source sentences

    Summary
    The liraglutide group showed lower cytokine levels compared to the placebo group during follow-up: Δ IL-6 (-28 [-182, 135] vs. 32 [-10.6, 70.7] pg/mL; p = 0.041) and Δ IL-10 (-0.01 [-2.2, 1.5] vs. 1.9 [-0.2, 6.1] pg/mL; p = 0.042), respectively.
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide prevented the increase in plasma IL-10 seen with placebo.

    In plain wordsIn brain-dead organ donors, liraglutide prevented the rise in blood IL-10 seen with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in IL-10 plasma level
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Delta IL-10
    −0.01 pg/mL
    liraglutide
    Delta IL-10
    1.9 pg/mL
    placebo

    Source sentences

    Summary
    The liraglutide group showed lower cytokine levels compared to the placebo group during follow-up: Δ IL-6 (-28 [-182, 135] vs. 32 [-10.6, 70.7] pg/mL; p = 0.041) and Δ IL-10 (-0.01 [-2.2, 1.5] vs. 1.9 [-0.2, 6.1] pg/mL; p = 0.042), respectively.
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide did not significantly alter liver expression of inflammatory genes.

    In plain wordsIn brain-dead organ donors, liraglutide did not change activity of inflammation genes in the liver.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver expression of inflammatory genes
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The administration of liraglutide did not significantly alter the expression of inflammatory
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide did not significantly alter liver expression of antiapoptotic genes.

    In plain wordsIn brain-dead organ donors, liraglutide did not change activity of cell-survival genes in the liver.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver expression of antiapoptotic genes
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The administration of liraglutide did not significantly alter the expression of inflammatory, antiapoptotic, endoplasmic reticulum stress, or antioxidant genes in the liver tissue.
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide did not significantly alter liver expression of endoplasmic reticulum stress genes.

    In plain wordsIn brain-dead organ donors, liraglutide did not change activity of cell-stress genes in the liver.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver expression of endoplasmic reticulum stress genes
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The administration of liraglutide did not significantly alter the expression of inflammatory, antiapoptotic, endoplasmic reticulum stress, or antioxidant genes in the liver tissue.
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide did not significantly alter liver expression of antioxidant genes.

    In plain wordsIn brain-dead organ donors, liraglutide did not change activity of antioxidant genes in the liver.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver expression of antioxidant genes
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The administration of liraglutide did not significantly alter the expression of inflammatory, antiapoptotic, endoplasmic reticulum stress, or antioxidant genes in the liver tissue.
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide did not affect liver protein expression, similar to gene expression.

    In plain wordsIn brain-dead organ donors, liraglutide did not change levels of tested proteins in the liver.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver protein expression (TNF, DDIT3, superoxide dismutase 2)
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Similar to gene expression, expressions of proteins in the liver were not affected by the administration of liraglutide.
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In brain-dead donors, liraglutide did not increase the organ recovery rate versus placebo.

    In plain wordsIn brain-dead organ donors, liraglutide did not increase the organ recovery rate compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeOrgan recovery rate
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Odds ratio
    1.2
    organ recovery

    Source sentences

    Summary
    Treatment with liraglutide did not increase the organ recovery rate [OR = 1.2 (95% CI: 0.2-8.6), p = 0.82].
    1 context sentence
    Summary · context
    Fifty brain-dead donors were randomized to receive subcutaneous liraglutide or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.